MX2009004982A - Derivados heterociclicos como inhibidores cetp. - Google Patents

Derivados heterociclicos como inhibidores cetp.

Info

Publication number
MX2009004982A
MX2009004982A MX2009004982A MX2009004982A MX2009004982A MX 2009004982 A MX2009004982 A MX 2009004982A MX 2009004982 A MX2009004982 A MX 2009004982A MX 2009004982 A MX2009004982 A MX 2009004982A MX 2009004982 A MX2009004982 A MX 2009004982A
Authority
MX
Mexico
Prior art keywords
cetp inhibitors
heterocyclic derivatives
cetp
compound
heterocyclic
Prior art date
Application number
MX2009004982A
Other languages
English (en)
Inventor
Masashi Kishida
Hidetomo Imase
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009004982A publication Critical patent/MX2009004982A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I), dicho compuesto es un inhibidor de CETP y además puede ser utilizado para el tratamiento de un trastorno o enfermedad mediada por CETP o en respuesta a la inhibición de CETP.
MX2009004982A 2006-11-15 2007-11-13 Derivados heterociclicos como inhibidores cetp. MX2009004982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124131 2006-11-15
PCT/EP2007/062274 WO2008058961A1 (en) 2006-11-15 2007-11-13 Heterocyclic derivatives as cetp inhibitors

Publications (1)

Publication Number Publication Date
MX2009004982A true MX2009004982A (es) 2009-05-20

Family

ID=37909477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004982A MX2009004982A (es) 2006-11-15 2007-11-13 Derivados heterociclicos como inhibidores cetp.

Country Status (11)

Country Link
US (1) US20100041705A1 (es)
EP (1) EP2086961A1 (es)
JP (1) JP2010509387A (es)
KR (1) KR20090080523A (es)
CN (1) CN101535293A (es)
AU (1) AU2007321283A1 (es)
BR (1) BRPI0718399A2 (es)
CA (1) CA2669221A1 (es)
MX (1) MX2009004982A (es)
RU (1) RU2009122504A (es)
WO (1) WO2008058961A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1968941A1 (en) * 2005-12-29 2008-09-17 Novartis AG Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp)
AR060873A1 (es) 2006-05-10 2008-07-16 Novartis Ag Derivados biciclicos como inhibidores de cetp
WO2007132906A1 (en) * 2006-05-11 2007-11-22 Novartis Ag Benzylamine derivatives as cetp inhibitors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
CN103351354B (zh) * 2013-06-09 2015-08-12 西安近代化学研究所 1-甲基-5-氨基四唑合成方法
CN103524445A (zh) * 2013-09-09 2014-01-22 南通市华峰化工有限责任公司 一种1-甲基-5氨基四氮唑的合成生产方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3285499A (en) * 1998-02-13 1999-08-30 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6653471B2 (en) * 2000-08-07 2003-11-25 Neurogen Corporation Heterocyclic compounds as ligands of the GABAA receptor
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2005233160B2 (en) * 2004-04-13 2011-06-02 Merck Sharp & Dohme Corp. CETP inhibitors
DK1848430T3 (da) * 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors

Also Published As

Publication number Publication date
EP2086961A1 (en) 2009-08-12
WO2008058961A1 (en) 2008-05-22
US20100041705A1 (en) 2010-02-18
BRPI0718399A2 (pt) 2014-03-11
CN101535293A (zh) 2009-09-16
JP2010509387A (ja) 2010-03-25
CA2669221A1 (en) 2008-05-22
RU2009122504A (ru) 2010-12-20
AU2007321283A1 (en) 2008-05-22
KR20090080523A (ko) 2009-07-24

Similar Documents

Publication Publication Date Title
TN2009000012A1 (en) Amino-piperidine derivatives as cetp inhibitors
MX2010006063A (es) Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
JO2732B1 (en) Organic compounds
MX2009006630A (es) Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
JO3114B1 (ar) مركبات بيريدازينون
SG171593A1 (en) Inhibitors of c-fms kinase
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
MD4582C1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
IN2012DN01273A (es)
GEP20115306B (es)
MX2009009699A (es) Compuestos amino-5-[4-(difluorometoxi)fenil sustituidos]-5-fenilim idazolona como inhibidores de beta-secretasa.
GEP20135957B (en) Heterocyclic compound and usage thereof
EA201070864A1 (ru) Новые гетероциклические соединения
MX2009004982A (es) Derivados heterociclicos como inhibidores cetp.
MX2012015098A (es) Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes).
WO2007139992A3 (en) ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
UA107784C2 (en) Inhibitor of melanin production
GEP20146201B (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
NZ593172A (en) 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
MX347619B (es) Polimorfos y sales de 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-p iperazinil] metil}-1,3-oxazol-2-il)-1h-indazol como inhibidores de pi3k para usarse por ejemplo en el tratamiento de trastornos respiratorios.
MX2009005249A (es) Compuestos organicos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal